SBTX.L

SkinBioTherapeutics Plc
SkinBioTherapeutics - Conversion Notice and Total Voting Rights
22nd July 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1849X
SkinBioTherapeutics PLC
22 July 2024
 

22 July 2024

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

 

Conversion Notice and Total Voting Rights

 

SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it received a Conversion Notice on 17 July 2024 from Macquarie ("Macquarie") for £160,000 of Convertible Bonds from the £5.0 million convertible bond facility announced on 25 January 2024. The Company has drawn a total of £1,600,000 under the Facility. Following this conversion, the balance of ourstanding bonds will be £480,000.

 

 

SkinBioTherapeutics will issue 1,989,879 ordinary shares of £0.01 per share ("Ordinary Shares") at a conversion price of 8.040687p per Ordinary Share.

 

Admission and Total Voting Rights

 

Application has been made for the 1,989,879 new ordinary shares, which will rank pari passu in all respects with the existing ordinary shares of the Company, to be admitted to AIM, which is expected to occur on or around 8.00 a.m. on 24 July 2024 ("Admission"). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 205,361,916.

 

The above figure of 205,361,916 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

-Ends-

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

 

 

 

For more information please contact:

 

SkinBioTherapeutics plc

Stuart J. Ashman, CEO

Manprit Randhawa, CFO

 

 

Tel: +44 (0) 191 495 7325

 

 

 

Cavendish Capital Markets Limited

(Nominated Adviser & Broker)

Giles Balleny, Dan Hodkinson (Corporate Finance)

Charlie Combe (Broking)

Dale Bellis, Tamar Cranford-Smith (Sales)

 

 

Tel: +44 (0) 20 7220 0500

Instinctif Partners (financial press)

Melanie Toyne-Sewell / Jack Kincade

Tel: +44 (0) 20 7457 2020

SkinBioTherapeutics@instinctif.com

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ALSRBMPTMTMTBAI]]>
TwitterFacebookLinkedIn